双重mTORC抑制在晚期/复发上皮性卵巢癌、输卵管癌或原发性腹膜癌(透明细胞、子宫内膜样、高级别浆液性类型及癌肉瘤)试验(DICE)的统计分析计划
DICE是一项II期国际多中心、平行组、优效性、1:1开放标签随机试验,计划纳入124例铂耐药卵巢癌女性(每臂62例),评估TAK228联合每周紫杉醇的疗效。本文为数据库锁定前制定的统计分析计划,详述主要终点总生存无进展生存期(PFS)及次要终点的分析原则与统计程序。
要点
- 主要终点为总无进展生存期(PFS),次要终点包括24周PFS、总缓解率(ORR)等。
- 计划样本量124例铂耐药卵巢癌女性,每治疗臂62例。
- 试验于2018年9月开始招募,2021年初中期分析建议继续试验。
核心结论
- DICE试验将确定在每周紫杉醇化疗基础上加用TAK228是否在参与者无进展生存期和总生存期方面显示统计学显著改善,且不良事件(AEs)和生活质量(QoL)不显著劣于标准治疗。
研究设计与样本
- II期国际多中心、平行组、优效性临床试验,1:1开放标签随机,计划样本量124例铂耐药卵巢癌女性(每治疗臂62例)。
主要发现
- 统计分析计划详细描述了主要终点总无进展生存期(PFS)及次要终点(24周PFS、ORR、DoR、TTP、4个月CBR、CA125缓解、OS、安全性和耐受性、EORTC QLQ-C30和EORTC QLQ-OV28生活质量问卷)的分析原则与统计程序,包括显著性水平、敏感性分析和依从性分析。
- 试验于2018年9月开始招募,2021年初进行中期分析,结果建议继续试验,招募正在进行,预计2021年底完成。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment for ovarian cancer includes platinum-based chemotherapy, but many women become resistant to chemotherapy, becoming platinum-resistant. Standard of care for these women is weekly paclitaxel chemotherapy, but cancers can often become paclitaxel resistant. TAK228, an investigational dual TORC1/2 inhibitor, is an oral therapy that can be added to standard treatment. The DICE trial is a phase II international multicentre, parallel-group, superiority clinical trial with 1:1, open label randomisation which has the aim of investigating the effectiveness of TAK228 plus weekly paclitaxel. The planned sample size is 124 women (62 per treatment arm) with platinum-resistant ovarian cancer. OBJECTIVE: To outline the planned analyses for DICE in a statistical analysis plan (SAP) before database hard lock and the start of analysis. This ensures that bias is minimised during the analysis phase. RESULTS: This SAP provides detailed descriptions of the analysis principles and statistical procedures for analysing primary and secondary outcomes of the trial. The primary outcome is overall progression-free survival (PFS). Secondary outcomes include progression-free survival (PFS) at 24 weeks, overall response rate (ORR), duration of response (DoR), time to progression (TTP), clinical benefit rate (CBR) at 4 months, Cancer Antigen 125 (CA125) response according to Gynaecological Cancer Intergroup (GCIG) criteria, overall survival (OS), safety and tolerability as assessed by adverse events and the quality-of-life questionnaires (EORTC QLQ-C30 and EORTC QLQ-OV28). This detailed description includes significance levels, sensitivity analyses and compliance analysis. DISCUSSION: The DICE trial will determine whether the addition of TAK228 to weekly paclitaxel chemotherapy shows a statistically significant improvement to participant's progression free and overall survival and that the adverse events (AEs) and quality of life (QoL) are not significantly worse than the standard treatment. The study commenced recruitment in September 2018. An interim analysis was performed in early 2021, the results of which advised continuation of the trial. The study recruitment is ongoing and is due to complete by the end of 2021. TRIAL REGISTRATION: ClinicalTrials.gov NCT03648489 . Registered on 27 August 2018.
引用
- de la Rosa CN, Krell J, Day E, et al. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE). Trials. 2022. PMID: 34986897. doi:10.1186/s13063-021-05669-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。